Background and purpose: The International League against Epilepsy (ILAE) updated the classifications of seizures and epilepsies in 2017. The 2017 classifications were compared with the 1980s classifications in rural China. Methods: People with epilepsy receiving treatment under the National Epilepsy Control Programme were recruited from rural areas in China. Their seizures and epileptic syndrome were classified using the 1980s ILAE classification system and then re-classified according to the 2017 system. Differences in seizure, epilepsy and aetiology classifications were identified. Results: A total of 597 individuals (58% males, aged 6-78 years) were included. Amongst them 535 (90%) had a single seizure type, 57 (9.55%) had two types and five (0.84%) had three. There was complete agreement between the 1981 and 2017 classifications for the 525 individuals with focal seizures. Seizures originally classified as generalized in 10 of 65 individuals were re-classified as unknown in the 2017 classification. Compared to the 1980s classifications, the proportion of individuals with unknown seizures and unknown epilepsy increased from 1.2% (7/597) to 2.8% (17/597, P = 0.002), and unknown aetiology increased from 32% (189/597: 182 cryptogenic and seven unclassified) to 39% (230/597; P < 0.001) in the 2017 classifications. Conclusions: The 1980s and 2017 classifications had 100% agreement in classifying focal seizures and epilepsy in rural China. A small but significant proportion of generalized seizures and epilepsy and aetiologies classified in the old classifications were re-classified to unknown in the new classifications. These results highlight the need for improvement in clinical evaluation of people with epilepsy in resource-poor settings.
Introduction
Accurate classification of seizure and epilepsy is critical for optimal clinical management, effective communication amongst healthcare providers and research. In 2017, the International League against Epilepsy (ILAE) presented a new classification scheme for seizures and epilepsies [1, 2] .
The new scheme has a number of important conceptual differences from the previous scheme in use since the 1980s [3, 4] . One of these is the requirement of a confidence level of at least 80% as a prerequisite to classify seizure type; otherwise it should be classified as unknown. Achieving the confidence level would probably involve evidence from investigations such as electroencephalography (EEG) and neuroimaging. The old system dichotomized epileptic syndromes into either generalized or focal but the new scheme introduced the category of 'combined' epilepsy type which aims to provide a more accurate description of some syndromes. There is also a greater emphasis on putative aetiologies at each classification step in the new scheme compared to the previous version. Epilepsy aetiology is now stratified at several levels allowing multiple aetiologies in a given individual.
Whilst the new scheme is generally welcomed it is important to evaluate its applicability in different clinical settings. Previous schemes have been evaluated mainly in specialized healthcare settings [5] [6] [7] . The great majority of people with epilepsy, however, live in rural areas or in resource-poor settings [8] .
The new classifications scheme was applied at primary care level in rural China and compared with the previous versions.
Methods

Participants
People with epilepsy aged 2-80 years were recruited from rural areas in four Chinese provinces (Henan, Hebei, Ningxia and Shanxi) between 1 July 2010 and 31 December 2012. They were receiving treatment in the National Epilepsy Control Programme which aims at delivering epilepsy care at primary and secondary level [8] . People with non-epileptic seizures, seizures related to alcohol or illicit drug abuse, or as a result of progressive, degenerative neurological or systemic disorders were excluded. Those in whom magnetic resonance imaging (MRI) was contraindicated (such as metallic implants or devices or with claustrophobia) were also excluded.
The study was approved by the Joint Chinese University of Hong Kong -New Territories East Cluster Research Ethics Committee (CRE-2010.185) in Hong Kong and the institutional review board of the Beijing Neurosurgical Institute in China. Written informed consent was obtained from all participants or their legal guardians.
Clinical assessments
Using predesigned epilepsy history and seizure classification questionnaires, primary care physicians interviewed participants or their carers to collect medical history and seizure information. The clinical questionnaire consisted of 19 points covering birth, developmental, family, epilepsy, other medical and drug history. The 33 questions of the seizure classification form covered a broad range of seizure semiology for classification in accordance with the updated ILAE terminology [9] . The questionnaires were developed based on those previously employed for seizure classification [10] [11] [12] . The questionnaires were piloted before deployment. Training and standardization workshops for the physicians involved were conducted by senior epileptologists (JWS and PK).
After the interview at primary care, participants underwent specialist neurological evaluation at the higher level of care (corresponding provincial hospitals) including history taking and physical examination. All underwent routine EEG and brain MRI using standardized protocols. Interictal EEG recordings were obtained according to the international 10-20 system. The recording and reporting protocols were in accordance with guidelines from the American Clinical Neurophysiology Society. MRI brain (1.5 T) was performed at the specialist centre following a common acquisition protocol. This consisted of a T1-weighted volumetric acquisition sequence with 1 mm partitions, oblique coronal dual-echo proton density and T2-weighted as well as fluid attenuated inversion recovery (FLAIR) sequences. The MRI was systematically evaluated on Osirix PACS (Pixmeo, Geneva) by qualified neuroradiologists (ID and CH).
Case classification
Based on all information collected at the rural clinic and provincial hospital each participant's seizure and epilepsy types were classified. All were first classified using the 1981 ILAE seizure classification and 1989 ILAE epilepsy classification system and then re-classified according to the 2017 ILAE seizure and epilepsy classifications. Two inter-rater agreement analyses were performed. In the first analysis, 60 (10%) individuals were randomly selected and classified by two epileptologists (JWS and PK) using the 1980s system. 
Statistical analysis
Descriptive analysis was performed to summarize demographics. McNemar's test was used to compare the differences in classifying seizures, epilepsies and aetiologies between the 1980s and 2017 classification schemes. All statistical tests were performed using Stata14 (StataCorp, College Station, TX, USA).
Results
Demographics
A total of 637 individuals were recruited and interviewed by rural physicians; one was excluded due to data entry issues and 39 were excluded as MRI incompatible. Amongst the 597 participants with evaluable datasets (seizure and epilepsy questionnaire, clinical data, EEG and MRI copies and reports from specialist hospitals), 344 (58%) were male. The median age at recruitment was 38 years [interquartile range (IQR) 27-48, range 6-78] and the median age of epilepsy onset was 14 years (IQR 6-25, range 0-66).
Seizure classification
Amongst the 597 participants, 535 (90%) had a single seizure type, 57 (9.55%) had two seizure types and five (0.84%) had three seizure types.
Amongst those with a single seizure type, 473 (88%) had focal seizures, 55 (10%) had generalized seizures and seven (1.31%) had unclassified seizures according to the 1981 seizure classification (Table 1) . For focal seizures, this was almost identical when using the matching terminology of the 2017 ILAE seizure classification (Table 2 ). Ten participants, however (Table S1 ), originally classified as having generalized seizures were re-classified as unknown according to the 2017 classification (Table 3) . Overall, the proportion of participants with unknown onset seizures increased slightly from 1.2% (7/597) in the 1989 scheme to 2.8% (17/597) using the 2017 classification (P = 0.002).
For participants with multiple seizure types, similar classifications were made when using the 1981 and 2017 schemes. Amongst the 57 with two seizure types, 51 were classified as having focal onset seizures (eight were simple partial or focal aware seizures and 43 were complex partial or focal impaired awareness seizures) and partial to secondarily generalized or focal to bilateral tonic-clonic seizures, and six only had generalized seizures [three generalized tonic-clonic seizure (GTCS) and absence, one GTCS and atonic, one GTCS and myoclonic, and one absence and atonic]. Amongst the five participants with three seizure types, three only had generalized seizures, one only had focal seizures and one had focal and generalized seizure using the 2017 system but was classified as having generalized onset seizures using the 1981 system. 
Epilepsy classification
Similar to seizure classifications, the 1989 and 2017 epilepsy classifications showed complete agreement when applied to 525 (88%) individuals with focal epilepsy ( Table 4 ). The 10 who had generalized seizures re-classified as unknown seizures under the 2017 seizure classification also had generalized epilepsy reclassified as unknown epilepsy. This led to an overall slight increase in the proportion of unknown type of epilepsy from 1.2% (7/597) in the 1989 scheme to 2.8% (17/597) in the 2017 scheme (P = 0.002). One participant (Table S2 , case 1) who was classified as generalized epilepsy under the 1989 classification was re-classified as having combined focal and generalized epilepsy using the new scheme.
Aetiology classification
According to the 1989 classification, the aetiologies of epilepsy were identified as idiopathic in 47 (7.9%) individuals, symptomatic in 361 (60%), cryptogenic in 182 (30%) and unclassified in seven (1.2%). By using the 2017 classification, aetiology was re-classified to unknown in nine (19%) of the individuals originally diagnosed with idiopathic aetiology owing to lack of family history and clinical associated syndromes, 44 (12%) of those with symptomatic aetiology owing to lack of clear epileptogenic lesion in MRI, and 170 (93%) of those with cryptogenic epilepsy (Table 5) . Twelve cryptogenic cases were re-classified as having genetic aetiology owing to strong family history. The number of epilepsy with unknown aetiology cases increased from 189 (32%, 182 cryptogenic and seven unclassified) in the 1989 classification to 230 (39%) cases in the 2017 classification (P < 0.001). In addition, 47 individuals with structural aetiology were also classified as having genetic (n = 14) and infectious aetiologies (n = 33).
Discussion
Since their release the new ILAE seizure and epilepsy classifications have been critically appraised [13] [14] [15] . This is one of the first studies to compare their applicability with the previous scheme in a rural area. An overall excellent agreement was found in classifying focal seizures and focal epilepsies and the main inconsistency was found in generalized seizures. The increase in unclassified cases was statistically significant but it only affected a small number of cases. A possible explanation for the discrepancy is the introduction of the '80% confidence level' concept, requiring more detailed clinical evidence for classification. For instance, an individual (Table S2 , case 2) was classified as having generalized seizure and generalized epilepsy with idiopathic aetiology by using the old classifications. In the 2017 scheme, he was classified as having unknown seizure and epilepsy type due to the lack of supportive evidence to attain the confidence level to make a diagnosis of generalized epilepsy. Therefore, the use of the 80% confidence level and more requirements for objective evidence in the 2017 classifications can help highlight the knowledge gap in the clinical evaluation of people with epilepsy. Another advantage of the 2017 classification method is that it includes some of the rarer seizure types, such as eyelid myoclonia and epileptic spasm, which were undetermined in the 1980s system. These seizure types were not seen in our cohort but their diagnosis often requires supportive findings from prolonged video-EEG recording which is generally only available in specialized settings.
According to the 2017 classifications, one individual with generalized epilepsy (Table S2 , case 1) was reclassified into the combined group. This change of epilepsy type provides a better representation of the individual's clinical manifestations and disease mechanism. Similar to the seizure classification, the proportion of individuals with unknown epilepsy has also risen since more objective evidence is required in the new scheme. For example, neuroimaging findings are required for allocation into the structural aetiology group (Table S2, case 3).
As more evidential findings are required in the new classifications, whilst seizure and epilepsy classifications were unchanged, the aetiology was re-classified as unknown in some cases due to lack of positive neuroimaging. This applied to people with a history of head trauma or birth hypoxia without abnormality on neuroimaging, despite the temporal association between the brain insult and onset of epilepsy. In these cases, technical limitations of the scanners or imaging acquisition protocols might have missed subtle cerebral damage.
In the new scheme, people with epileptic encephalopathy and associated learning disability were classified as unknown aetiology due to the lack of genetic evidence or a positive family history (Table S2 , case 4). Progress in understanding the genomics of epilepsy has driven genetics to become a separate aetiological category. An autosomal dominant trait can be used as evidence for a genetic aetiology but, for the majority of individuals, finding the underlying genetic cause is challenging, particularly for people living in resource-poor settings.
Infection was listed as an independent aetiology in the 2017 classification. As a result, 38 participants were classified into this group. This can potentially help clinicians determine treatment strategy. In the study cohort, no individual was classified as having metabolic or immune aetiology. The identification of these two aetiologies requires support from molecular biology and genetic examination techniques, which are generally not available in the rural setting.
Our study has its limitations. All the participants underwent EEG and MRI which are not routinely available in the rural area; hence potentially fewer individuals in such setting might have sufficient evidence to reach a confident classification. Assessment of inter-rater agreement involved epilepsy experts and may yield different findings amongst primary care physicians or local neurologists. The schemes agreed perfectly for focal onset seizure subtypes, probably due to the fact that the new classifications just applied new terminologies for focal onset seizures so there was wide overlap between the new and old classifications. There was also bias towards convulsive seizures (either generalized or focal onset) and 88% of the cohort had focal onset seizures. A possible explanation is that people with non-convulsive seizures were less likely to seek medical care in this rural setting. The cohort, however, reflects the real-world situation of epilepsy care in resource-poor areas. Future study in other healthcare settings is needed to evaluate the agreement between the two classifications for nonconvulsive seizures.
In conclusion, our study provided insight into the applicability of the new classification scheme in areas with scarce healthcare resources. Compared with the previous system, the new classification has advantages in allowing a clearer description of the clinical manifestations, aetiology and mechanisms of seizure and epilepsy. The introduction of combined epilepsy types and multiple aetiologies removes the mutually exclusive approach in the previous scheme. These advantages can help physicians establish more appropriate treatment plans and may improve prognosis. The new system, however, requires a higher level of confidence and standard of clinical evidence. Further research is needed to evaluate the impact of the new classification scheme on clinical practice in terms of the investigation and treatment of epilepsy in areas with scarce medical resources. grants and honoraria from UCB, Eisai, Bial and Janssen which are involved in the manufacturing of antiepileptic drugs. PK has received speaker or consultancy fees and/or research grants from Eisai, GlaxoSmithKline, Johnson & Johnson, Pfizer and UCB Pharma. The authors confirm that they have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.
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